C4 Therapeutics
MA - WatertownBiotechnology
Focus: C4 Therapeutics is a biotech company focused on ubiquitin-proteasome system (UPS) based therapeutics and protein degradation mechanisms, operating in oncology with early-stage pipeline assets.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Open Jobs
5-2 this month
Stable — net -2 jobs in 30d
3 added, 5 removed. Backfill posture.
Should You Work at C4 Therapeutics?
AI assessmentBest suited for scientists/CMC professionals seeking deep UPS-platform expertise in an early-stage setting; career risk for those prioritizing near-term revenue stability or management scale.
Why Work Here
- Pioneering platform in protein degradation/UPS therapeutics offers deep scientific differentiation and potential to define a therapeutic class
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
cemsidomide
Multiple MyelomaClinical Trials (1)
NCT04756726Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Phase 1Help build intelligence for C4 Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.